Company Directory

Clinical-stage antifungal drug developer targeting invasive fungal infections

F2G is a clinical-stage biopharmaceutical company developing novel antifungal therapies for life-threatening invasive fungal infections. The company discovered the orotomides, a new class of antifungal agents that selectively inhibit fungal dihydroorotate dehydrogenase, a mechanism of action distinct from all approved antifungals. Its lead compound, olorofim, is an oral agent in Phase 3 development for invasive aspergillosis and has received FDA Breakthrough Therapy Designation for multiple indications.

Polymer-embedded antimicrobial technology for infection prevention in medical devices

Zonova is a biotech company developing patented antimicrobial technology embedded into medical device polymers at the manufacturing stage. The technology creates a protective surface that continuously kills a broad spectrum of pathogens, including drug-resistant strains such as MRSA. Applications span catheters, cannulas, endotracheal tubes, and surgical sutures. Zonova's commercial model is B2B licensing to medical device manufacturers, within a One Health approach to tackling antimicrobial resistance.

Microbiome modulator ingredients for metabolic health and disease prevention

OptiBiotix Health is a biotechnology company developing and licensing microbiome modulator products for use in food ingredients, dietary supplements, and nutraceuticals. Its portfolio includes patented prebiotic and probiotic formulations targeting weight management, cholesterol reduction, cardiovascular health, and gut microbiome diversity. Products are licensed to food and supplement manufacturers globally. The company operates through subsidiaries including OptiBiotix Ltd and holds a majority stake in SkinBioTherapeutics plc and ProBiotix Health Ltd.

Bacterial bioinoculant replacing synthetic nitrogen fertiliser in crops

NetZeroNitrogen is a biotechnology company developing a biological alternative to synthetic nitrogen fertiliser based on a naturally occurring endophytic bacterium that fixes atmospheric nitrogen within plant cells. The technology is designed to reduce dependence on synthetic nitrogen inputs, lowering associated greenhouse gas emissions while maintaining or improving crop yields. Initial target applications are in rice cultivation, with field trials underway across Southeast Asia.

Global crop protection, seed and digital agriculture solutions provider

Corteva Agriscience UK is the British operating subsidiary of Corteva, Inc., a global agriculture company formed from the DuPont Pioneer, Dow AgroSciences and DuPont Crop Protection businesses. The company supplies Pioneer and Brevant seed varieties, crop protection products including herbicides, insecticides and fungicides, and an expanding range of biological products derived from microorganisms. Corteva also provides UK farmers with agronomic support and digital agriculture tools, helping growers improve productivity while reducing reliance on synthetic inputs.

Contract research and analytical services for food and health industries

QIB Extra is a wholly owned commercial subsidiary of Quadram Institute Bioscience, providing contract research, analytical services, and consultancy to companies in the food, nutrition, and health sectors. Operating from Norwich Research Park, it gives commercial clients access to the facilities and scientific expertise of the Quadram Institute on a fee-for-service basis. Services include applied microbiology, food safety testing, bioactive analysis, gut health research, and sequencing. Clients range from SMEs to large multinationals.

C. elegans whole-organism platform for preclinical drug and compound screening

Magnitude Biosciences Limited is a contract research organisation providing preclinical drug discovery and compound screening services using Caenorhabditis elegans as a whole-organism model. Its proprietary biophotonics platform enables automated, high-throughput, non-invasive monitoring of health and lifespan metrics across large worm populations, supporting compound library screening, pathway analysis, microbiome assessment, and toxicology studies. The platform accelerates early compound triage for pharmaceutical, biotechnology, and nutrition clients, reducing reliance on mammalian models.

AI-powered microbiome and phage therapy platform for gut disorders

GutSee Health is a biotechnology company developing precision microbiome therapies for gut disorders including irritable bowel syndrome and inflammatory bowel disease. Its AI discovery platform integrates multi-omics and microbiome data to identify molecular disease signatures and therapeutic targets. A parallel programme uses machine learning to design targeted bacteriophage interventions that selectively remove harmful gut microbes and address antimicrobial-resistant wound infections.

Microbiome platform optimising hydroponic crop performance

Concert Bio is an agricultural biotechnology company developing microbial products to optimise crop performance in hydroponic greenhouses. Its platform combines the world's largest hydroponic microbiome database with machine learning to identify beneficial microbes tailored for soilless growing systems. The company's first commercial product has demonstrated average yield improvements of 9.9% across multiple crops in commercial grower trials. Concert Bio serves greenhouse growers across the UK and Europe.

Biopesticides, insect lures and smart traps for sustainable pest management

Razbio is a Welsh biotech company developing sustainable pest management solutions for agriculture and public health. Its product portfolio spans fungal biopesticides, AI-identified insect lures and repellents, and automated AI-equipped smart traps for field pest monitoring. Validated products include a lure for Western Flower Thrips deployed at commercial UK strawberry farms. The company also develops bio-fertilisers and soil treatments targeting crop yield optimisation. Research partnerships include University College London via the AgRIA programme.

Bacteria-based platform for carbon-negative water treatment

Lux Biotech is an industrial biotechnology company developing bacteria-based products for water treatment and pollution remediation. Using organic waste effluents as bacterial feedstock, the company produces microbial solutions that replace chemicals in sewage and water treatment processes. The approach is carbon-negative and designed to reduce greenhouse gas emissions associated with conventional treatment infrastructure. Applications extend to agriculture. Lux Biotech has received Innovate UK grant funding and collaborates with Swansea University.

Clinical skin microbiome testing and multi-omic ingredient analysis platform

Sequential Skin is a biotechnology company providing non-invasive clinical microbiome testing and multi-omic analysis services to the personal care and pharmaceutical industries. Using patch-based sampling and next-generation sequencing, the company quantifies how ingredients and formulations affect the skin microbiome and host biomarkers. Its proprietary dataset of over 50,000 samples and 4,000 ingredients underpins an AI-powered discovery engine for identifying and optimising next-generation bioactive compounds.